Direct Oral Anticoagulants (DOACs) Device Market Size, Share, Trends, & Industry Analysis Report By Product Type, By Disease Indication, By Application, By Patient Demographic, By End User, and By Region – Market Forecast, 2025–2034

The direct oral anticoagulants device market size is expected to reach USD 64.83 Billion by 2034, according to a new study by Polaris Market Research. The report “Direct Oral Anticoagulants (DOACs) Device Market Share, Size, Trends, Industry Analysis Report: By Product Type, By Disease Indication, By Application, By Patient Demographic, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Direct Oral Anticoagulants (DOACs) Device coagulation devices are specialized diagnostic tools designed to monitor anticoagulation levels in patients using direct oral anticoagulants, ensuring safe and effective therapeutic outcomes. These devices play a critical role in clinical decision-making by providing accurate, real-time insights into coagulation status, particularly in stroke prevention, venous thromboembolism management, and post-surgical care.

They are essential for improving treatment precision, minimizing adverse events, and supporting individualized patient care across hospitals, ambulatory centers, and homecare settings. Advancements in assay sensitivity, device portability, and digital connectivity are enhancing diagnostic efficiency and expanding the utility of these systems in both acute and chronic care pathways. Their integration into routine clinical workflows contributes to better patient outcomes, streamlined monitoring, and overall healthcare cost optimization.

Direct Oral Anticoagulants (DOACs) Device Market Report Highlights

In terms of application, the stroke prevention segment led the market in 2024, primarily due to rising prevalence of atrial fibrillation and other cardiovascular conditions requiring anticoagulation therapy.

In terms of end user, the hospitals are expected to register the highest CAGR during the forecast period, as they serve as the primary healthcare setting for comprehensive management of both acute thrombotic events and chronic anticoagulation requirements.

North America captured the largest revenue share in the DOAC device market in 2024, owing to its sophisticated healthcare infrastructure, high thromboembolic disease burden, and widespread clinical adoption of direct oral anticoagulants across care settings.

The Asia Pacific market is anticipated to demonstrate consistent growth, fueled by increasing healthcare expenditure, greater awareness of coagulation disorders, and a progressive transition toward preventive care and personalized treatment approaches.

A few global key market players include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Sysmex Corporation, Instrumentation Laboratory (Werfen), Nihon Kohden Corporation, Diagnostica Stago, Coag-Sense, HemoSonics, Sekisui Medical Co., Ltd., Grifols S.A., and Helena Laboratories Corporation.

Polaris Market Research has segmented the market report on the basis of product type, disease indication, application, patient demographic, end user, and region:

By Product Type Outlook (Revenue, USD Billion, 2020–2034)

Factor Xa Inhibitors

Direct Thrombin Inhibitors

By Disease Indication Outlook (Revenue, USD Billion, 2020–2034)

Atrial Fibrillation

Deep Vein Thrombosis (DVT)

Pulmonary Embolism (PE)

Heart Attacks

Post-Surgical Thromboprophylaxis

Others

By Application Outlook (Revenue, USD Billion, 2020–2034)

Stroke Prevention

Venous Thromboembolism Prevention

Treatment of Acute Thrombotic Events

Long-Term Prophylaxis

Other Application

By Patient Demographic Outlook (Revenue, USD Billion, 2020–2034)

Paediatric

Adult

Geriatric

By End User Outlook (Revenue, USD Billion, 2020–2034)

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Homecare Settings

Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more